Pirouz M Daftarian 1 , Geoffrey W Stone , Leticia Kovalski , Manoj Kumar , Aram Vosoughi , Maitee Urbieta , Pat Blackwelder , Emre Dikici , Paolo Serafini , Stephanie Duffort , Richard Boodoo , Alhelí Rodríguez-Cortés , Vance Lemmon , Sapna Deo , Jordi Alberola , Victor L Perez , Sylvia Daunert , Arba L Ager
Dec 1 2013
Amphotericin B (AmB), the most effective drug against leishmaniasis, has serious toxicity. As Leishmania species are obligate intracellular parasites of antigen presenting cells (APC), an immunopotentiating APC-specific AmB nanocarrier would be ideally suited to reduce the drug dosage and regimen requirements in leishmaniasis treatment. Here, we report a nanocarrier that results in effective treatment shortening of cutaneous leishmaniasis in a mouse model, while also enhancing L. major specific T-cell immune responses in the infected host.